Depression following the initiation of glucagon‐like‐peptide‐1 receptor agonist therapy: A multinational self‐controlled case series study

Eric Yuk Fai Wan has received research grants from the Health Bureau, the Hong Kong Research Grants Council, Narcotics Division, Security Bureau, Social Welfare Department, Labour and Welfare Bureau of the Government of the Hong Kong SAR and National Natural Science Foundation of China; serves on member of Core Team for Expert Group on Drug Registration of Pharmacy and Poisons Board and is the director of Advance Data Analytics for Medical Science (ADAMS) Limited (HK). These are outside the submitted work. Ian Chi Kei Wong received research grants outside of submitted work from European Commission, Research Grants Council of the Hong Kong Special Administrative Region of the People's Republic of China, Health and Medical Research Fund of the Government of the Hong Kong Special Administrative Region of the People's Republic of China and Amgen; consulting fees from IQVIA and World Health Organization; served as a member of Pharmacy and Poisons Board of Hong Kong and was the founder and director of Therakind Limited (UK). He is the non-executive director of Jacobson Pharma Corp. Ltd. in Hong Kong and director of Advance Data Analytics for Medical Science (ADAMS) Limited (HK), Healthcare Innovation Technology Service (HITS) Limited (UK) and OCUS Innovation Limited (HK, Ireland and UK). He received honorarium from Takeda as a speaker of continuous professional education study day. EWYC reports grants from the Hong Kong Research Grants Council of the Government of the Hong Kong SAR, Research Fund Secretariat of the Food and Health Bureau, National Natural Science Fund of China, Bayer, Bristol-Myers Squibb, Pfizer, Janssen, Amgen, Takeda, RGA Reinsurance Company, AstraZeneca, Narcotics Division of the Security Bureau of the Hong Kong Special Administrative Region, Innovation and Technology Commission of the Government of the Hong Kong Special Administrative Region, Novartis, and honorarium from Hospital Authority, outside the submitted work. Data may be obtained from a third party and are not publicly available. Taiwan site: Raw data were generated at Taiwan's National Health Insurance Research Database. Derived data supporting the findings of this study are available from the corresponding author (Huang-Tz Ou) on request. HK and UK sites: The underlying data supporting this analysis cannot be directly shared as they are obtained under licence from IQVIA (for UK data) and owned by Hospital Authority of Hong Kong (for HK data), and data custodians have not given permission for sharing. Table S1: Characteristics of cases included in the SCCS Table S2: Subgroup analyses pooled results across all sites Table S3: Sensitivity analyses pooled results across all sites Table S4: Subgroup and sensitivity analyses results of each individual site Figure S1: Flowchart for selection of SCCS cases Figure S2: Study design Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.